Introduction: Merkel cell carcinoma (MCC) is an aggressive neuroendocrine carcinoma of the skin. The use of checkpoint inhibitors has shown good results in the treatment of advanced MCC. Avelumab is a PD-L1 inhibitor able to prevent the inactivation of the T lymphocytes. We report a serie of consecutive MCC cases treated with Avelumab in two centres
Aim(s): To evaluate the activity and safety of Avelumab in MCC
Materials and methods: We performed a retrospective analysis of all MCC patients (pts) treated with Avelumab, 600 mg median dose once every 14 days, between March 2018 and November 2019
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: Ivana Puliafito
To read results and conclusion, please login ...
Further abstracts you may be interested in